Weight-loss drug with hormone coil for treating early uterine cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests combining a weight-loss medication (mazdutide) with a hormone-releasing intrauterine device (LNG-IUS) to treat early-stage uterine cancer or precancerous changes while preserving fertility. It aims to help patients who are overweight or obese and wish to avoid hysterectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 45
- You have been diagnosed with atypical endometrial hyperplasia or early-stage, low-grade endometrioid endometrial cancer that has not spread into the uterine muscle
- Your tumor is estrogen receptor-positive
- You have a body mass index (BMI) of 28 or higher, or a BMI of 24 or higher with at least one weight-related condition such as diabetes, high blood pressure, or fatty liver
- You are willing to delay standard surgery and follow the study's close monitoring plan
- You have not previously received fertility-sparing treatment for this condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This study tests whether a three-month program that includes weight-loss medications and hormone therapy before surgery is better than surgery alone for women with early-stage endometrial cancer and severe obesity. The goal is to see if this approach improves surgical outcomes and overall health.
This trial tests whether combining lifestyle changes (diet and exercise) with a medication called mazdutide can help adults with obesity lose weight and keep it off. Mazdutide is an injectable medication that may help reduce appetite and support weight management over 2 years.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.